Danovitch, G.M., Cohen, D.J., Weir, M.R., Stock, P.G., Bennet, W.M., Christensen, L.L. and Sung, R.S. (2005) Current status of kidney and pancreas transplantation in the United States, 1994-2003. American Journal of Transplantation, 5, 904-915. doi:10.1111/j.1600-6135.2005.00835.x

has been cited by the following article:

• TITLE: Transfusion, erythropoiesis-stimulating agent therapy, and kidney transplant wait time

  AUTHORS: Robert M. Perkins, H. Lester Kirchner, Rajesh Govindasamy

  KEYWORDS: Anemia; Blood Transfusion; Erythropoietin; Kidney Disease; Transplantation

  JOURNAL NAME: Open Journal of Internal Medicine, Vol.2 No.1, March 28, 2012

  ABSTRACT: Aim: Anemia is highly prevalent among patients wait-listed for renal transplant, and management with blood transfusion or erythropoietin stimulating agents may impact transplant wait time. The purpose of this study was to examine the impact of blood transfusion and erythropoiesis stimulating agent therapy on renal transplant wait time. Methods: We retrospectively analyzed all adult patients listed for first deceased donor kidney transplantation at two transplant centers in Central Pennsylvania between 2004 and 2008. The exposures of interest were blood transfusion and erythropoietin stimulating agent therapy. Cox proportional hazards were used to model time to deceased donor kidney transplant. Results: Among 407 patients listed for transplant, 84 received a deceased donor kidney during a median follow-up of 26.3 months. In an adjusted Cox proportional hazards model, with erythropoiesis stimulating agent and transfusion both treated as time-dependent exposures, UNOS inactive status at listing date (hazard ratio [HR] 0.81; 95% CI 0.73 - 0.89; P